首页> Communications biology> Design and optimisation of dendrimer-conjugated Bcl-2/x<sub>L</sub> inhibitor, AZD0466, with improved therapeutic index for cancer therapy.

Design and optimisation of dendrimer-conjugated Bcl-2/x<sub>L</sub> inhibitor, AZD0466, with improved therapeutic index for cancer therapy.

导出 LinkOut

翻译打印收藏纠错

第一作者： Claire M,Patterson

第一单位： Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK.

作者： Claire M,Patterson ^[1] ; Srividya B,Balachander ^[2] ; Iain,Grant ^[3] ; Petar,Pop-Damkov ^[2] ; Brian,Kelly ^[4] ; William,McCoull ^[5] ; Jeremy,Parker ^[1] ; Michael,Giannis ^[4] ; Kathryn J,Hill ^[3] ; Francis D,Gibbons ^[2] ; Edward J,Hennessy ^[2] ; Paul,Kemmitt ^[5] ; Alexander R,Harmer ^[6] ; Sonya,Gales ^[6] ; Stuart,Purbrick ^[6] ; Sean,Redmond ^[7] ; Matthew,Skinner ^[6] ; Lorraine,Graham ^[1] ; J Paul,Secrist ^[2] ; Alwin G,Schuller ^[2] ; Shenghua,Wen ^[2] ; Ammar,Adam ^[2] ; Corinne,Reimer ^[2] ; Justin,Cidado ^[2] ; Martin,Wild ^[5] ; Eric,Gangl ^[2] ; Stephen E,Fawell ^[2] ; Jamal,Saeh ^[2] ; Barry R,Davies ^[5] ; David J,Owen ^[4] ; Marianne B,Ashford ^[8]

作者单位： Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK. ^[1] Oncology R&D, AstraZeneca, Boston, MA, 02451, USA. ^[2] Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, SK10 2NA, UK. ^[3] Starpharma, 4-6 Southampton Crescent, Abbotsford, VIC, 3067, Australia. ^[4] Oncology R&D, AstraZeneca, Cambridge, CB4 0FZ, UK. ^[5] Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, CB4 0FZ, UK. ^[6] Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Boston, MA, 02451, USA. ^[7] Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK. Marianne.Ashford@astrazeneca.com. ^[8]

医学主题词动物(Animals);抗肿瘤药(Antineoplastic Agents);树状聚合物(Dendrimers);狗(Dogs);女(雌)性(Female);人类(Humans);男(雄)性(Male);小鼠(Mice);小鼠, 近交C57BL(Mice, Inbred C57BL);小鼠, SCID(Mice, SCID);肿瘤(Neoplasms);原癌基因蛋白质c-bcl-2(Proto-Oncogene Proteins c-bcl-2);大鼠(Rats);大鼠, Wistar(Rats, Wistar);肿瘤细胞, 培养的(Tumor Cells, Cultured);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays);bcl-X蛋白质(bcl-X Protein)

DOI 10.1038/s42003-020-01631-8

PMID 33495510

发布时间 2021-10-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Communications biology

2021年4卷1期

112页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览2

点击下载本期目录封面

Communications biology

2021年4卷1期

112页

检索历史清除

Design and optimisation of dendrimer-conjugated Bcl-2/x<sub>L</sub> inhibitor, AZD0466, with improved therapeutic index for cancer therapy.

Communications biology

相似文献

同项目论文

Communications biology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Design and optimisation of dendrimer-conjugated Bcl-2/x<sub>L</sub> inhibitor, AZD0466, with improved therapeutic index for cancer therapy.

Communications biology

相似文献

同项目论文

Communications biology

相关期刊

检索历史清除